HUMAN UMBILICAL VEIN ENDOTHELIAL CELL (HUVEC) RESISTANCE TO APOPTOSIS IS MEDIATED BY ACTIVATION OF NF-KAPPAB

2004 ◽  
Vol 13 (3) ◽  
pp. 127
Author(s):  
Andrea R King ◽  
Sarah J Rowe ◽  
Sheila E Francis ◽  
Moira KB Whyte ◽  
David C Crossman
Keyword(s):  
Endothelial Cell ◽  
Umbilical Vein ◽  
Human Umbilical Vein ◽  
Nf Kappab

Circulating miR-3656 induces human umbilical vein endothelial cell injury by targeting eNOS and ADAMTS13

2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Jikang Shi ◽  
Yaxuan Ren ◽  
Sainan Liu ◽  
Qian Zhao ◽  
Fei Kong ◽  
...  
Keyword(s):  
Endothelial Cell ◽  
Cell Injury ◽  
Umbilical Vein ◽  
Endothelial Cell Injury ◽  
Human Umbilical Vein

Curculigoside attenuates human umbilical vein endothelial cell injury induced by H2O2

2010 ◽  
Vol 132 (1) ◽  
pp. 233-239 ◽  
Author(s):  
Yun Kai Wang ◽  
Ya Jun Hong ◽  
Mao Wei ◽  
Ye Wu ◽  
Zhao Quan Huang ◽  
...  
Keyword(s):  
Endothelial Cell ◽  
Cell Injury ◽  
Umbilical Vein ◽  
Endothelial Cell Injury ◽  
Human Umbilical Vein

THE LUPUS ANTICOAGULANT DOES NOT INHIBIT THE RELEASE OF PROSTACYCLIN FROM HUMAN ENDOTHELIAL CELLS

1987 ◽  
Author(s):  
W Petraiuolo ◽  
E Bovill ◽  
J Hoak
Keyword(s):  
Endothelial Cells ◽  
Endothelial Cell ◽  
Causal Relationship ◽  
Lupus Anticoagulant ◽  
Umbilical Vein ◽  
Human Endothelial Cells ◽  
Human Umbilical Vein ◽  
Blood Institute ◽  
Specialized Center ◽  
National Heart Lung

Decreased endothelial cell production of prostacyclin (PGI2) in response to the lupus anticoagulant has been previously demonstrated, and postulated to have a causal relationship to the thrombotic events associated with the lupus anticoagulant. Five patients who exhibited the anticoagulant were studied in an effort to determine if a relationship exists between exposure of endothelial cells to the lupus anticoagulant and decreased production of prostacyclin (PGI2). Human endothelial cells derived from human umbilical vein grown in culture were exposed to IgG fractions of patient plasmas containing the lupus anticoagulant. The amount of PGI2 released was determined by radioimmunoassay for 6-keto-PGF-l-alpha. The average PGI2 release in the controls was 20.6 picomol/500,000 endothelial cells, whereas those cells exposed to the lupus anticoagulant had a range of 25 to 114 picmol/500,000 cells. We were unable to demonstrate inhibition of the release of PGI2 by human endothelial cells, following exposure to the lupus anticoagulant.(Supported by NIH Grant HL 33723-2 and a Specialized Center of Research in Thrombosis Award HL 35058-01 from the National Heart, Lung and Blood Institute.)

Sign in / Sign up

Export Citation Format

Share Document